Sanoptis
Since Telemos partnered with Sanoptis management to establish the company in 2018, it has developed into a leading provider of high quality and innovative ophthalmology treatments in Europe. At the time of the exit, the company operated over 250 facilities and performed over 1.3 million conservative and 170,000 surgical procedures annually. Sanoptis has rapidly grown into a market leader in Germany and Switzerland through acquisitions and organic initiatives.
Telemos signed an agreement to sell Sanoptis to family-backed investment holding company Groupe Bruxelles Lambert (“GBL”) on the 20th April 2022. The transaction ensured that Sanoptis would continue to get the support needed for the next phase of the company’s growth across Europe.
“When we founded Sanoptis, we believed that Telemos was the right partner. This was absolutely confirmed during our successful collaboration. Open-minded, unbureaucratic, entrepreneurial, supportive – and quick decision making processes, without which we would never have been able to get from zero to number one in less than four years”
Volker Wendel,
CEO of Sanoptis